del Carmen Sancho M, Breslow R, Sloane D, Castells M. Chem Immunol Allergy. Integrating science into oncology for a better patient outcome, ESMO Designated Centres Community Session, Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the. Abe et al. Check the latest publications and updates here to make sure you dont miss anything. 2017 Jul 1;28(suppl_4):iv119-iv142. Markman, M. (2007). Reactions to taxenes including paclitaxel and docetaxel present with pain as a neuromuscular symptoms in up to 4% of the patients. Severe reactions are less frequent and may be fatal without appropriate intervention. These risk factors can help identify patients at greater risk of developing hypersensitivity. Disclaimer. Lacouture, V. Sibaud, P.A. doi: 10.1016/j.ygyno.2006.10.047, Shah, A. C., Minturn, J. E., Li, Y., Belasco, J. Assess for pustules or blisters or erosions in addition to areas of "dusky erythema" which may feel painful to palpation. 17, 11411145. HHS Vulnerability Disclosure, Help Care. For more detailed information on the cookies we use, please check our Privacy Policy. Pediatric. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). 10.1016/annonc/annonc687, Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC), Targeted Therapies and Precision Oncology, Interpreting Oncological Study Publications, Cancer Diagnosis and Treatment Evaluation, Cancer Treatment in Special Clinical Situations, Clinical Pharmacology of Anti-Cancer Agents, Controversies in upper GI oncology: ESMO Open Podcasts, International Prognostic Index Tools for Lymphoma, Anti-Cancer Agents and Biological Therapy, Drug-Drug Interactions with Kinase Inhibitors, PARP inhibition and DNA Damage Response (DDR), Cancer Aetiology, Epidemiology and Prevention, Cancer in Special situations (pregnancy, young, elderly, hereditary), Multikinase Inhibitor-Related Skin Toxicity, Precision Medicine and Validated Biomarkers, ESMO Recommendations in Precision Medicine. 3, 10 In subsequent trials, 11 - 16 patients were premedicated . European Hematology Association (EHA) and European . Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Carboplatin and other paltins such as cisplatin and oxaliplatin reactions include classical symptoms of anaphylaxis with cutaneous, respiratory, cardiovascular, and gastrointestinal symptoms. No use, distribution or reproduction is permitted which does not comply with these terms. (2003). Oncol. Before Among these 75 women, 16 (21.3%) experienced severe hypersensitivity reactions (grades 3 and 4). (2007). Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies. (2013). Epub 2017 Feb 24. Curr Pharm Des. Ann. Analysis and interpretation of data: Y-HT, Y-JT, H-CH, Y-YC, and W-FC. Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. A cumulative carboplatin dose >4,000 mg significantly positively correlated with carboplatin hypersensitivity. J. Gynecol. Close monitoring is warranted for patients with any one of these three risk factors who are receiving carboplatin. Most events occurred during chemotherapy. The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with >8 cycles or dose >3,500 mg. hypersensitivity and pneumonitis not otherwise specified. The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Clinical Practice Guidelines Prevention and Management of Dermatological Toxicities Related to Anticancer Agents, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. Open. PH IV/PH FDC SC for HER2-positive BC were well tolerated, with few grade 3 anaphylaxis/hypersensitivity events reported with PH IV and no grade 3 related events with PH FDC SC. doi: 10.1200/JCO.2003.02.153, Parmar, M. K., Ledermann, J. doi: 10.7759/cureus.24515. 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. Thus, the risk of severe carboplatin-related hypersensitivity may influence its usage in gynecological cancers, and it is important to develop protocols to reduce this risk, especially the risk of severe reactions. 2023 Mar 15;210(6):709-720. doi: 10.4049/jimmunol.2100485. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. Guidelines | ESMO All funding for this site is provided directly by ESMO. The histological type was serous in 381 patients (51.8%) and clear cell in 148 patients (20.1%). The term 'hypersensitivity' should be used to describe objectively reprodu- cible symptoms or signs initiated by exposure to a dened stimu- lus at a dose tolerated by normal persons. Carboplatin-related hypersensitivity reactions sometimes result in premature discontinuation of treatment (Schwartz et al., 2007). eCollection 2022. II., Markman, M., Brown, J., et al. PDF Management of Immune-related Adverse Events in Patients Treated - Asco Careers. 2012;97:217-33. doi: 10.1159/000335637. Critical revision: C-AC. MeSH In our study, 36% of the patients with carboplatin-related hypersensitivity reactions had a history of drug allergies. Abe, A., Ikawa, H., and Ikawa, S. (2010). Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines (2017) 8 Pager Instructions Coverage Begins March 1, 2019 Coverage Ends: TBD 1. . Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients. The imaging findings follow the American Thoracic Society and European Respiratory Society classification of interstitial pneumonia. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population. Symptoms and signs of hypersensitivity reactions amendable to desensitization. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Blood. The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically relevant topics and are produced by 20-40 key experts in the field. S M S, Naveen NR, Rao GK, Gopan G, Chopra H, Park MN, Alshahrani MM, Jose J, Emran TB, Kim B. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. 24, 2432. There was a striking difference in PFSmedian 16.8 versus 5.6 months, HR 0.52 (highly significant)with the difference in PFS sustained at 12- and 18-month landmarks. Lancet 361, 20992106. Oncology 61, 129133. Front Oncol. Patients without ovarian cancer were excluded from retrospective analysis of details of hypersensitivity reactions recorded contemperaneously between April 2019 - January 2020 on excel and chemocare (CIS Oncology, Belfast, UK) by the treating practitioner. 2022 Apr 26;14(4):e24515. HHS Vulnerability Disclosure, Help Published in 2020 - Ann Oncol (2020) Authors: M.E. However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. doi: 10.1007/s10147-014-0731-1. doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations Front Immunol. These ESMO Clinical Practice Guidelines provide recommendations on the prevention/management of dermatological toxicities. LUGANO-MADRID, 09 September, 2017 -The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for . The .gov means its official. doi: 10.1111/j.1525-1438.2007.01063.x, Genc, D. B., Canpolat, C., and Berrak, S. G. (2012). Management of infusion reactions to systemic anticancer therapy: ESMO Cancer 104, 640643. A three-step method was developed to identify hypersensitivity reactions, including anaphylaxis, in a clinical trial database and could be applied to investigational drugs to improve early detection and monitoring of potential safety concerns, subsequent patient safety management strategies, and potentially programme-wide drug development Educate. The cumulative incidence of carboplatin-related hypersensitivity reactions increased with the number of carboplatin cycles (Figure 1A) and increasing dose (Figure 1B), especially at >8 cycles or a dose >3,500 mg. (2005). ESMO is a Swiss-registered not-for-profit organisation. J. Clin. Analysis included treatment cycle, causative drug, severity of reaction as per CTCAE v4 . doi: 10.1016/j.ygyno.2006.04.002, Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. official website and that any information you provide is encrypted This Webinar series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing the guideline. 8:800. doi: 10.3389/fphar.2017.00800. By delivering the target dose of the drug by small incremental doubling doses (Figure 3), the threshold for anaphylaxis is re-established at each step and never reaches that of the initial triggering dose. Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. (1999). Gynecol. doi: 10.3322/caac.21332, Sliesoraitis, S., and Chikhale, P. J. 103, 608613. Authors S Rosell 1 , I Blasco 1 , L Garca Fabregat 1 , A Cervantes 1 , K Jordan 2 ; ESMO Guidelines Committee Optimal debulking surgery was performed in 491 patients (66.8%). 24, 342351. J. Med. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Patients who previously received platinum compounds were excluded. Unable to load your collection due to an error, Unable to load your delegates due to an error. A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. ESMO 2019 Congress | OncologyPRO Wang, H. B., Shen, K., Yang, J. X., Huang, H. F., Li, Y., Wu, M., et al. National Library of Medicine TABLE 3 Table 3. We also recorded the procedures applied to treat the hypersensitivity reactions and efforts to manage the side effects of carboplatin administration. Careers. doi: 10.1016/j.ygyno.2007.06.016, Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., et al. Educate. The ESMOClinical Practice Guidelines(CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings ofevidence-based medicine. Interactive/Pocket Guideline Interactive/Pocket Guideline Constipation in Advanced Cancer 1 2 3 Though the characteristics of carboplatin-related hypersensitivity reactions are widely reported, limited data are available regarding such reactions in different types of patients. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . The site is secure. Author Mariana Castells 1 Affiliation 1 Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . The ESMO Clinical Practice Guidelines, prepared and reviewed by leading experts and based on the findings of evidence-based medicine, provide you with a set of recommendations to help patients with the best care options. Clipboard, Search History, and several other advanced features are temporarily unavailable. Monitor. doi: 10.1016/j.ygyno.2016.09.027, Bruchim, I., Goldberg, A., Fishman, A., and Confino-Cohen, R. (2014). Gender, age, ethnicity and race were similar between subgroups as were objective response rates (ORR) (64% CPI-treated v 62% CPI-nave). A spotlight on alkaloid nanoformulations for the treatment of lung cancer. Res. In the present study, 61 patients with carboplatin-related hypersensitivity were rechallenged with carboplatin. The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.ESMO-MCBS scores are included in ESMO Clinical Practice Guidelines to help further guide treatment decisions. 2014;24(2):72-9; quiz 2 p following 79. Genc et al. S.M. These patients were provided with intravenous fluid infusion and medications, including corticosteroids, antihistamines, and oxygen application. doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). Gynecol. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. See this image and copyright information in PMC. Disclaimer. Cancer 20, 385393. Here's a summary of the new ESMO guidelines in 5 key areas: . Cancer. The median patient age was 56 years (range 1694 years). The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Information for media including press accreditation. sharing sensitive information, make sure youre on a federal 28, 33233329. Yamamoto A, Kamoi S, Matsuda S, Kawase R, Nakanishi K, Suzuki S. Medicines (Basel). (2009) reported the successful re-treatment of the majority of patients with previous carboplatin-related hypersensitivity reactions. The left side, Putative mechanism of protection against, Putative mechanism of protection against anaphylaxis during human desensitizations. All accepted abstracts are available in theESMO 2017 Abstract Book. Clipboard, Search History, and several other advanced features are temporarily unavailable. For more detailed information on the cookies we use, please check our Privacy Policy. Swain: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Advisory Role: Exact Sciences (Genomic Health); Financial Interests, Personal, Advisory Role: Molecular Templates; Financial Interests, Personal, Advisory Role: Silverback Therapeutics; Financial Interests, Personal, Advisory Role: Tocagen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Natera; Financial Interests, Personal, Advisory Role: Beijing Medical Foundation; Financial Interests, Personal, Advisory Board: Inivata; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Research Grant: KailosGenetics; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: BMS; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Lilly; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Daiichi-Sankyo; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Caris Life Sciences; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Tan: Non-Financial Interests, Institutional, Research Grant: Genentech/Roche; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Immunomedics; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Athenex; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Merck; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. L. Gianni: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: ADC Therapeutics; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Genentech, Inc.; Financial Interests, Personal, Advisory Board: Genomic Health; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Oncolytics Biotech; Financial Interests, Personal, Advisory Board: Odonate Therapeutics; Financial Interests, Personal, Advisory Board: Onkaido Therapeutics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Taiho Pharmaceutical; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Synthon and Zymeworks; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Zymeworks; Financial Interests, Institutional, Research Grant: Revolution Medicines; Financial Interests, Personal, Advisory Role: Forty Seven; Financial Interests, Personal, Advisory Role: Metis Precision Medicine; Financial Interests, Personal, Advisory Role: Menarini Ricerche; Financial Interests, Personal, Advisory Role: Synaffix; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Revolution Medicines; Non-Financial Interests, Personal, Other, Patent; EPA 12195182.6 12196177.5-Roche, pending (coinventor): Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Kmmel: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Personal, Advisory Role: Exact Science; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Daiichi Sanyko; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Somatex; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: PFM medical; Financial Interests, Personal, Advisory Role: Lily; Non-Financial Interests, Personal, Other: Roche; Non-Financial Interests, Personal, Other: Daiichi Sankyo; Non-Financial Interests, Personal, Other: Lily; Non-Financial Interests, Personal, Other: Sonoscape; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Dang: Financial Interests, Personal, Other, Honoraria: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Honoraria: Genentech, Inc.; Financial Interests, Personal, Other, Honoraria: Daiichi-Sankyo; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Puma Biotechnology; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Other, Travel expenses: Celgene; Financial Interests, Personal, Other, Travel expenses: Roche; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Celgene; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: MSD; Financial Interests, Personal, Other, Honoraria: Tesaro; Financial Interests, Personal, Other, Honoraria: Lily; Financial Interests, Personal, Other, Travel expenses: Pfizer; Financial Interests, Personal, Other, Honoraria: Seagen; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. J. O'Shaughnessy: Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: Agendia; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Genentech, Inc.; Financial Interests, Personal, Advisory Role: Immunomedics; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Odonate; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Puma; Financial Interests, Personal, Advisory Role: Prime Oncology; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Advisory Role: Seattle Genetics; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Aguila: Financial Interests, Personal, Full or part-time Employment, Clinical Scientist/Medical Director: F. Hoffmann-La Roche Ltd.; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Heeson: Financial Interests, Personal, Full or part-time Employment: Roche Products Ltd.; Financial Interests, Personal, Stocks/Shares: Roche Products Ltd.; Non-Financial Interests, Personal, Other, Patent; PH FDC SC: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Macharia: Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffman-La Roche.
Tiger Shark Swim Team, Articles E